Burns Matteson Capital Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$545K Buy
3,477
+31
+0.9% +$4.65K 0.17% 103
2026
Q1
$526K Buy
+3,446
New +$528K 0.19% 109

Other funds holding NVS

Burns Matteson Capital Management's NVS Position: Q2 2026 in Review

Burns Matteson Capital Management increased its Novartis (NVS) stake by 0.9% in Q2 2026, buying an estimated $4.65K and bringing the position to 3,477 shares worth $545K. The position accounts for 0.17% of the portfolio, ranked #103.

Burns Matteson Capital Management first reported a position in NVS in Q1 2026 and has held it in 2 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Burns Matteson Capital Management held 3,477 shares of Novartis worth $545K as of Q2 2026.
  • Burns Matteson Capital Management bought 31 Novartis shares in Q2 2026, an estimated $4.65K.
  • Novartis made up 0.17% of Burns Matteson Capital Management's portfolio in Q2 2026, its #103 holding.
  • Burns Matteson Capital Management first reported a position in Novartis in Q1 2026 and has held it in 2 quarters since.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Burns Matteson Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.